Enfuvirtide Subcutaneous and Rimactane
Determining the interaction of Enfuvirtide Subcutaneous and Rimactane and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Coadministration with rifampin has been shown to have minimal effects on the pharmacokinetics of enfuvirtide. According to the manufacturer, rifampin (600 mg once daily for 10 days) decreased the steady-state trough plasma concentration (Cmin) of enfuvirtide (90 mg twice a day) by 15% in 12 HIV-positive subjects. The peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of enfuvirtide were not affected.
- "Product Information. Fuzeon (enfuvirtide)." Roche Laboratories, Nutley, NJ.
Generic Name: enfuvirtide
Brand name: Fuzeon
Synonyms: Enfuvirtide
Generic Name: rifampin
Brand name: Rifadin, Rifadin IV, Rimactane
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Enfuvirtide Subcutaneous-Rimantadine
- Enfuvirtide Subcutaneous-Rimantadine Hydrochloride
- Enfuvirtide Subcutaneous-Rimexolone
- Enfuvirtide Subcutaneous-Rimexolone Ophthalmic
- Enfuvirtide Subcutaneous-Rimso-50
- Enfuvirtide Subcutaneous-Rinvoq
- Rimactane-Engerix-B
- Rimactane-Engerix-B Pediatric
- Rimactane-Enjuvia
- Rimactane-Enjuvia Oral
- Rimactane-Enlon
- Rimactane-Enlon-Plus